ForumIAS LATEST
- SFG FRC 2027 | Program starts from 15th Dec. 2026 | Admissions open for Tranche-1 Entrance Test till 25th Oct. 2026 Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 21st October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
News: The World Health Organization will provide 70,000 Ervebo vaccine doses to the Democratic Republic of Congo during the Bundibugyo Ebola outbreak.
About Ervebo Vaccine
- Ervebo is an approved Ebola vaccine that has proved safe and effective against the Zaire strain of Ebola virus.
- Manufactured by: It is manufactured by Merck.
- Vaccine Type: It is a replication-competent, live, attenuated recombinant vaccine that uses vesicular stomatitis virus (VSV) as a vector.
- Working Mechanism: A small gene from the Ebola virus is added to the vesicular stomatitis virus (VSV) to create the vaccine virus.
- Since it does not contain the whole Ebola virus, it cannot cause Ebola.
- The vaccine virus acts like a natural infection and trains the immune system to recognise and fight the Ebola virus.
- Administration: It is given as a single dose to individuals aged 12 months and above.
- Limited Protection: ERVEBO does not provide protection against other species of orthoebolaviruses or orthomarburgviruses.
